Medroxyprogesterone

Dosage for Medroxyprogesterone varies significantly depending on the condition being treated and the route of administration.

For Secondary Amenorrhea

• Oral: The typical dose is 5 mg to 10 mg taken daily for 5 to 10 days. Withdrawal bleeding usually occurs within 3 to 7 days after stopping the medication.

For Abnormal Uterine Bleeding (AUB)

• Oral: 5 mg to 10 mg daily for 5 to 10 days, beginning on the 16th or 21st day of the menstrual cycle as directed by a physician.

For Contraception

• Intramuscular (IM): 150 mg injected once every 13 weeks (3 months). If the interval exceeds 13 weeks, a pregnancy test must be performed before the next injection.
• Subcutaneous (SC): 104 mg injected once every 12 to 14 weeks.

For Endometrial or Renal Carcinoma

• IM Injection: Initially, 400 mg to 1000 mg per week. If improvement is noted within weeks or months, the dose may be tapered to a maintenance level of 400 mg per month.

Medroxyprogesterone is generally not approved for use in pediatric patients before the onset of menarche (the first menstrual period). For adolescent females who have reached menarche, the contraceptive dosage is the same as the adult dose. However, healthcare providers must exercise extreme caution due to the potential impact of the drug on bone mineral density (BMD) during the critical years of adolescent bone accretion.

Renal Impairment

The pharmacokinetics of Medroxyprogesterone have not been extensively studied in patients with renal disease. However, since the drug is primarily metabolized by the liver, significant dose adjustments are usually not required for patients with mild to moderate renal impairment. Close monitoring is still advised.

Hepatic Impairment

Medroxyprogesterone is contraindicated in patients with significant liver dysfunction or active liver disease. In patients with mild hepatic impairment, the drug should be used with caution, as its metabolism may be slowed, leading to increased systemic exposure.

Elderly Patients

There is limited data on the use of Medroxyprogesterone in patients over age 65 for non-oncological reasons. When used in postmenopausal hormone therapy, the lowest effective dose should be used for the shortest duration possible, in line with the Women's Health Initiative (WHI) guidelines.

• Oral Tablets: May be taken with or without food. If stomach upset occurs, taking it with a meal may help. Try to take the dose at the same time each day to maintain consistent hormonal levels.
• Injectable Forms: These must be administered by a healthcare professional. The site of injection should not be massaged after administration to ensure the 'depot' remains intact for slow release.
• Storage: Store tablets and un-used injection vials at room temperature (20°C to 25°C / 68°F to 77°F). Protect from light and do not freeze.

• Oral: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose.
• Injection: If you are more than 1 or 2 weeks late for your injection, you may not be protected against pregnancy. Use a backup contraceptive method (like condoms) and contact your doctor immediately for a pregnancy test and to reschedule your shot.

Signs of overdose may include severe nausea, vomiting, breast tenderness, dizziness, abdominal pain, and irregular vaginal bleeding. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention. While Medroxyprogesterone is generally not acutely toxic, supportive care is the primary treatment for overdose.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as this can cause hormonal imbalances or unintended pregnancy.

Patients taking Medroxyprogesterone frequently report the following symptoms, which are often related to the body adjusting to the synthetic hormone:

• Menstrual Irregularities: This is the most common side effect. It includes spotting, breakthrough bleeding, or a complete absence of periods (amenorrhea), especially with the injectable form. After one year of use, approximately 55% of women using the injection report amenorrhea.
• Weight Gain: Many patients experience an increase in weight, often attributed to increased appetite or fluid retention. Studies have shown an average gain of 5 to 8 pounds over the first two years of use.
• Headache: Mild to moderate tension-type headaches are common.
• Abdominal Pain or Discomfort: Often described as bloating or cramping.
• Nervousness and Dizziness: Some patients feel a sense of jitteriness or mild lightheadedness.

• Mood Changes: This includes irritability, mild depression, or anxiety.
• Breast Tenderness: Similar to the feeling experienced during early pregnancy or just before a period.
• Decreased Libido: A noticeable reduction in sexual desire.
• Acne and Skin Rashes: Hormonal shifts can trigger breakouts or localized skin reactions.
• Insomnia: Difficulty falling or staying asleep.
• Injection Site Reactions: For the injectable form, patients may experience redness, swelling, or a small permanent 'dimple' (skin indentation) at the site of the shot.

• Hirsutism: Excessive growth of hair on the face or body.
• Alopecia: Thinning of scalp hair.
• Galactorrhea: Unexpected nipple discharge.
• Glucose Intolerance: A slight rise in blood sugar levels, which may be significant for pre-diabetic patients.
• Melasma: Dark, discolored patches on the skin, usually on the face, exacerbated by sun exposure.

> Warning: Stop taking Medroxyprogesterone and call your doctor immediately if you experience any of these symptoms.

• Blood Clots (Thromboembolism): Symptoms include sudden shortness of breath (Pulmonary Embolism), pain/swelling in one leg (Deep Vein Thrombosis), or sudden chest pain.
• Stroke or Heart Attack: Symptoms include sudden numbness or weakness (especially on one side of the body), severe headache, slurred speech, or vision changes.
• Vision Loss: Sudden partial or complete loss of vision, or bulging of the eyes (Proptosis).
• Severe Depression: Thoughts of self-harm or deep, persistent feelings of hopelessness.
• Liver Dysfunction: Jaundice (yellowing of the skin or eyes), dark urine, and upper right abdominal pain.
• Anaphylaxis: Severe allergic reaction characterized by hives, swelling of the face/throat, and difficulty breathing.

• Bone Mineral Density (BMD) Loss: Prolonged use of the injectable form (Depo-Provera) is associated with a significant loss of bone density. While this is often partially reversible after stopping the drug, it may increase the risk of osteoporosis and fractures later in life.
• Delayed Return to Fertility: After stopping the injectable form, it can take an average of 10 months (and sometimes up to 18 months) for ovulation and regular menstruation to return.

The FDA has issued a Black Box Warning for Medroxyprogesterone (specifically the injectable form) regarding Bone Mineral Density. The warning states that use of the injection may cause significant loss of BMD. The loss is greater the longer the drug is used and may not be completely reversible. It is recommended that the drug be used as a long-term birth control method (e.g., longer than 2 years) only if other birth control methods are inadequate. Additionally, it should not be used as a primary treatment for endometriosis unless other therapies have failed.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Medroxyprogesterone is a powerful hormonal medication that requires careful medical supervision. It should only be used after a full discussion of risks and benefits with a qualified healthcare provider. Patients must be aware that this medication does not protect against HIV infection or other sexually transmitted infections (STIs).

1. Bone Mineral Density (BMD) Loss: Long-term use of medroxyprogesterone acetate injection may result in significant loss of bone mineral density. This loss may be particularly concerning in adolescents and young adults during the bone-building years. It is unknown if use during adolescence will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.

2. Cardiovascular Risks and Malignancy (Oral/HRT): When used in combination with estrogens for postmenopausal therapy, there is an increased risk of myocardial infarction (heart attack), stroke, invasive breast cancer, and venous thromboembolism (blood clots). These risks were highlighted by the Women's Health Initiative (WHI) study.

3. Dementia: The Women's Health Initiative Memory Study (WHIMS) found an increased risk of developing probable dementia in postmenopausal women age 65 or older treated with estrogen plus progestin.

• Allergic Reactions: While rare, anaphylaxis (severe allergic reaction) has been reported. Patients with a known allergy to Medroxyprogesterone or any ingredients in the formulation must avoid use.
• Thromboembolic Disorders: The drug should be discontinued immediately if there is a suspected or confirmed blood clot, stroke, or pulmonary embolism. Patients with a history of these conditions are generally advised against using hormonal contraceptives.
• Ectopic Pregnancy: Healthcare providers should be alert to the possibility of ectopic pregnancy (pregnancy outside the uterus) in women who become pregnant while using Medroxyprogesterone or who complain of severe abdominal pain.
• Liver Disease: Because the drug is metabolized by the liver, it can worsen existing liver conditions. If jaundice or abnormal liver function tests occur, the drug should be stopped.
• Depression: Patients with a history of clinical depression should be monitored closely. If the depression recurs to a serious degree, the medication should be discontinued.
• Fluid Retention: Medroxyprogesterone may cause fluid retention; therefore, patients with conditions like epilepsy, migraine, asthma, or cardiac/renal dysfunction require careful monitoring.

• DEXA Scans: For long-term users of the injection, periodic Dual-Energy X-ray Absorptiometry (DEXA) scans may be recommended to monitor bone density.
• Blood Pressure: Regular monitoring is necessary as hormonal therapy can cause hypertension (high blood pressure).
• Mammograms and Pelvic Exams: Annual breast and pelvic examinations are essential for women on long-term therapy to screen for malignancies.
• Liver Function Tests (LFTs): May be required if symptoms of hepatic distress appear.

Medroxyprogesterone may cause dizziness or fatigue in some patients. If you experience these symptoms, avoid driving or operating heavy machinery until you know how the medication affects you.

While there is no direct contraindication between alcohol and Medroxyprogesterone, excessive alcohol consumption can increase the risk of liver strain and may exacerbate side effects like dizziness or headaches. Alcohol also contributes to bone density loss, potentially compounding the drug's effect on the skeleton.

When stopping Medroxyprogesterone for menstrual regulation, a 'taper' is typically not required, but patients should expect a withdrawal bleed within a few days. For those stopping the injection, be prepared for a significant delay (months) before regular cycles and fertility return.

> Important: Discuss all your medical conditions, including any history of blood clots, liver disease, or breast cancer, with your healthcare provider before starting Medroxyprogesterone.

• Certain Breast Cancer Medications: Medroxyprogesterone should not be used in combination with specific hormonal therapies for breast cancer unless specifically directed by an oncologist, as it may interfere with the efficacy of the cancer treatment.
• Known Pregnancy: It is absolutely contraindicated during pregnancy as it may cause harm to the developing fetus.

• Aminoglutethimide: This medication, often used to treat Cushing's syndrome or breast cancer, can significantly decrease the blood levels of Medroxyprogesterone (by up to 70%), potentially rendering it ineffective.
• CYP3A4 Inducers: Drugs that speed up liver enzymes can lower the concentration of Medroxyprogesterone in the blood. Examples include:
• Rifampin (an antibiotic)
• Phenytoin, Carbamazepine, Phenobarbital (anti-seizure medications)
• Bosentan (for pulmonary hypertension)
• Anticoagulants: Medroxyprogesterone may alter the effectiveness of blood thinners like Warfarin. Patients on anticoagulants require frequent monitoring of their INR (blood clotting time).

• Antidiabetic Agents: Medroxyprogesterone can decrease glucose tolerance, which may require an adjustment in the dosage of insulin or oral diabetes medications (like Metformin).
• Corticosteroids: There may be an additive effect on fluid retention and glucose metabolism when used with drugs like Prednisone.
• Thyroid Hormones: Estrogen/progestin therapy can increase levels of thyroid-binding globulin, potentially requiring an increase in thyroid hormone replacement (e.g., Levothyroxine).

• Grapefruit Juice: While not as severely impacted as other drugs, grapefruit juice is a CYP3A4 inhibitor and may theoretically increase the levels of Medroxyprogesterone in the blood, potentially increasing side effects.
• High-Fat Meals: When taking the oral form, a high-fat meal can significantly increase the absorption and peak concentration (Cmax) of the drug.

• St. John's Wort: This popular herbal supplement for depression is a potent inducer of CYP3A4. It can lower the levels of Medroxyprogesterone, which is particularly dangerous for those using it for contraception, as it may lead to unintended pregnancy.
• Calcium and Vitamin D: Because of the risk to bone mineral density, patients on Medroxyprogesterone are often encouraged to take calcium and vitamin D supplements, though these do not 'interact' negatively with the drug; rather, they provide a protective benefit.

Medroxyprogesterone can interfere with the results of several laboratory tests:

• Metyrapone Test: May decrease the response to this test used for adrenal function.
• Glucose Tolerance Test: May show increased blood sugar levels.
• Coagulation Tests: May show increases in prothrombin and factors VII, VIII, IX, and X.
• Thyroid Function Tests: May show altered levels of T4 and T3 due to changes in binding proteins.

For each major interaction, the management strategy usually involves either choosing an alternative medication, adjusting the dose of the interacting drug, or increasing the frequency of clinical monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.

There are several conditions where Medroxyprogesterone must NEVER be used because the risks far outweigh any potential benefits:

1. 1Known or Suspected Pregnancy: Medroxyprogesterone is not effective for terminating a pregnancy and may cause developmental abnormalities in the fetus if exposure occurs during the first trimester.
2. 2Active Thrombophlebitis or Thromboembolic Disorders: This includes a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or recent stroke/heart attack. The drug can increase the 'stickiness' of the blood, leading to fatal clots.
3. 3Undiagnosed Vaginal Bleeding: Before starting hormonal therapy, the cause of any abnormal bleeding must be determined to rule out uterine or cervical cancer.
4. 4Known or Suspected Malignancy of the Breast: Many breast cancers are hormone-sensitive; adding a progestin can stimulate the growth of these tumors.
5. 5Severe Liver Dysfunction: Patients with active hepatitis, cirrhosis, or liver tumors cannot safely metabolize the drug.
6. 6Missed Abortion: Use is contraindicated in cases where a fetus has died in the womb but has not been expelled.

These conditions require a careful risk-benefit analysis by a physician:

• History of Depression: May be worsened by hormonal shifts.
• Diabetes Mellitus: Requires close monitoring of blood sugar levels.
• Hyperlipidemia: Progestins can sometimes negatively affect cholesterol profiles (lowering HDL or 'good' cholesterol).
• Migraine with Aura: May increase the risk of stroke in these patients.
• Bone Disease: Patients with existing osteoporosis or risk factors for fractures (like eating disorders or long-term steroid use).

Patients who have had a severe allergic reaction to other progestins (such as Norethindrone or Megestrol) may have a cross-sensitivity to Medroxyprogesterone. Additionally, some injectable formulations contain methylparaben and propylparaben, which can cause allergic reactions in sensitive individuals.

> Important: Your healthcare provider will evaluate your complete medical history, including any family history of cancer or blood clots, before prescribing Medroxyprogesterone.

Medroxyprogesterone is classified by the FDA as Pregnancy Category X for contraceptive use. This means that studies in animals or humans have demonstrated fetal abnormalities, and the risk of the drug in pregnant women clearly outweighs any possible benefit. If a patient becomes pregnant while on the drug, it should be discontinued immediately. There is a slightly increased risk of low birth weight and neonatal jaundice if the drug is present during pregnancy, although it is not considered a potent teratogen (substance causing birth defects) in the same way some other drugs are.

Medroxyprogesterone does pass into breast milk. However, studies have shown that it does not appear to adversely affect the quantity or quality of the milk, nor does it negatively impact the growth and development of the nursing infant. In many clinical guidelines, the progestin-only injection is considered a preferred contraceptive method for breastfeeding mothers, typically initiated 6 weeks postpartum to ensure lactation is well-established.

As noted previously, Medroxyprogesterone is not indicated before menarche. In adolescent females, the primary concern is the impact on bone mineral density. Because the teenage years are a critical window for reaching peak bone mass, the use of Depo-Provera should only be considered after discussing other options (like IUDs or implants) that do not carry the same risk of bone loss.

In older women, Medroxyprogesterone is primarily used as part of hormone replacement therapy (HRT) or for cancer treatment. According to the Beers Criteria (guidelines for safe medication use in seniors), clinicians should avoid using the combination of estrogen and progestin in postmenopausal women due to the increased risk of breast cancer and cardiovascular events. If used, it should be at the lowest dose for the shortest time.

There are no specific GFR-based (Glomerular Filtration Rate) dose adjustments provided by the manufacturer. However, because the drug can cause fluid retention, patients with end-stage renal disease (ESRD) or those on dialysis must be monitored for worsening edema (swelling) or hypertension.

Medroxyprogesterone is contraindicated in severe hepatic impairment (Child-Pugh Class C). In patients with moderate impairment (Child-Pugh Class B), the drug's metabolism is significantly reduced, and it should generally be avoided unless the clinical need is absolute and no alternatives exist.

> Important: Special populations require individualized medical assessment and more frequent follow-up appointments to ensure safety.

Medroxyprogesterone acetate (MPA) is a synthetic 17-alpha-hydroxyprogesterone derivative that acts as a potent Progesterone Receptor Agonist. By binding to nuclear progesterone receptors, it modulates gene expression in the hypothalamus, pituitary, and reproductive tissues.

1. 1Gonadotropin Suppression: It inhibits the mid-cycle surge of Luteinizing Hormone (LH), which prevents follicular maturation and ovulation.
2. 2Endometrial Transformation: It converts a proliferative endometrium into a secretory one. In the absence of estrogen, it causes thinning (atrophy) of the endometrium.
3. 3Cervical Mucus Alteration: It increases the thickness of cervical mucus, preventing sperm transport.
4. 4Antineoplastic Effect: In high doses, it produces a progestational effect on the endometrial cancer cells, potentially leading to cellular differentiation and decreased tumor growth.

The onset of action for the oral form is rapid, with effects on the uterine lining seen within days. For the contraceptive injection, protection is immediate if given within the first 5 days of a normal menstrual period. The duration of effect for a single 150 mg IM injection is at least 13 weeks. Tolerance does not typically develop to the contraceptive or endometrial effects.

| Parameter | Value |

|---|---|

| Bioavailability | 0.6% to 10% (Oral, highly variable) |

| Protein Binding | 90% to 95% (Primarily to Albumin) |

| Half-life | 12-17 hours (Oral); 40-50 days (IM Depot) |

| Tmax | 2-4 hours (Oral); 4-20 days (IM Depot) |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Renal (variable), Fecal (major) |

• Molecular Formula: C24H34O4
• Molecular Weight: 386.5 g/mol
• Solubility: Practically insoluble in water; freely soluble in chloroform; sparingly soluble in alcohol.
• Structure: A white to off-white, odorless crystalline powder. It is a steroid nucleus with an acetate group at the 17-position and a methyl group at the 6-position.

Medroxyprogesterone is a Progestin. It is related to other medications in this class such as Norethindrone, Levonorgestrel, and Megestrol. While the prompt mentioned 'Estrogen [EPC]', it is important to clarify that Medroxyprogesterone is used to counteract the effects of estrogen on the uterus, thereby preventing cancer.